Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

106 results about "Upper third" patented technology

Multiple phase foaming personal cleansing products

The present invention relates to personal care foaming and cleansing products comprising multiple phases which are separate and distinct and comprise at least one surfactant solution having a density or specific gravity of approximately 1.0. In a two-phase composition, a second separated phase may comprise cosmetically acceptable oily materials as emollients / conditioners having a density greater than that of the surfactant solution. In a three phase composition, an additional phase may comprise a low density emollient / conditioning compound(s) as an upper third phase. Thus, two, three or even four phase foaming bath products, shampoos and skin cleansers can be produced that can be differentially colored to enhance the visual separation of the layers and will provide foaming, cleaning, conditioning and emolliency in a unique and attractive manner.
Owner:ALZO INTTERNAT

Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning

Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and / or post stroke.
Owner:HEALTHPARTNERS RESEACH FOUND

Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning

ActiveUS20070092500A1Preventing and minimizing and treating neurologic complicationAvoid side effectsOrganic active ingredientsBiocideAntioxidantNose
Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and / or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.
Owner:HEALTHPARTNERS RESEACH FOUND

Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia

Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and / or post stroke.
Owner:HEALTHPARTNERS RESEACH FOUND

Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Methods and compositions for preventing and treating the damaged and / or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and / or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.
Owner:FREY II WILLIAM H +2

Equipment storage and transport apparatus

An equipment storage and transport apparatus includes a bucket having an interior chamber to store and carry items of equipment, a handle terminating at opposite ends being attached at opposite upper first locations on the bucket, cup-shaped support members attached at opposite lower second locations on the bucket angularly displaced from the first locations, loop-shaped retainer members attached at opposite upper third locations on the bucket spaced above the second locations and angularly displaced from the first locations, and a seat on the bucket bottom for the user to sit on when the bucket is inverted. The handle is configured to enable a user to grip it in order to lift and carry the bucket. The support members are configured to receive and hold the ends of elongated equipment items. The retainer members are configured to position the elongated equipment items upright relative to the support members.
Owner:SPADACCINI GEORGE M

Surveillance video oriented bearded face detection method

ActiveCN104616006AReduce the chance of being falsely detected as a moving objectGood quality extractCharacter and pattern recognitionPattern recognitionHaar classifier
The invention relates to a surveillance video oriented bearded face detection method. The method mainly used for processing the surveillance videos and comprises the following steps: reading a video file into a computer, decoding, and obtaining a region with human upper body moving targets by using an improved background subtraction method and a human upper body HOG classifier; then, aiming at the upper one third part of the human upper body moving region, detecting the possible face region in the part by adopting a face Haar classifier, and intercepting the lower half part of the face region as a beard detection region; finally, carrying out scale normalization for the region, then calculating the horizontal texture complexity, and judging whether beards exist or not. The method utilizes the motion feature and the morphological feature of the surveillance video oriented bearded faces, can reliably detect the bearded face targets in the walking and running front upright bodies.
Owner:湖南智慧平安科技有限公司

Method for production of a semiconductor structure

A method for producing a semiconductor structure including preparing a semiconductor substrate, and generating a lower first, a middle second and an upper third masking layer on a surface of the semiconductor substrate. The method further includes forming at least one first window in the upper third masking layer, structuring the middle second masking layer using the first window for transferring the first window, structuring the lower first masking layer using the first window for transferring the first window, and enlarging the first window to form a second window. The method for further includes restructuring the middle second masking layer using the second window for transferring the second window, structuring the semiconductor substrate, using the structured lower third masking layer, restructuring the lower first masking layer using the second window, and restructuring the semiconductor substrate using the restructured lower third masking layer.
Owner:POLARIS INNOVATIONS

Methods for preventing and treating post-traumatic stress disorder (PTSD)

Methods for preventing and / or treating symptoms of Post-Traumatic Stress Disorder (PTSD) are provided. The preferred method comprises administration of an effective amount of insulin to the upper one-third of a mammal's, preferably a human, nasal cavity, thereby enabling the administered at least one effective amount of insulin to bypass the patient's blood-brain barrier and be directly delivered to the patient's CNS. Another embodiment comprises utilizing vasoconstrictors to enhance targeting of an effective amount of insulin to the CNS while reducing non-target exposure.
Owner:HEALTHPARTNERS RESEACH FOUND

Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity

ActiveUS7776312B2Avoid side effectsStimulate and stabilize HIF-1αBiocideOrganic active ingredientsNervous systemNose
Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and / or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.
Owner:HEALTHPARTNERS RESEACH FOUND

Method for production of a semiconductor structure

A method for producing a semiconductor structure including preparing a semiconductor substrate, and generating a lower first, a middle second and an upper third masking layer on a surface of the semiconductor substrate. The method further includes forming at least one first window in the upper third masking layer, structuring the middle second masking layer using the first window for transferring the first window, structuring the lower first masking layer using the first window for transferring the first window, and enlarging the first window to form a second window. The method for further includes restructuring the middle second masking layer using the second window for transferring the second window, structuring the semiconductor substrate, using the structured lower third masking layer, restructuring the lower first masking layer using the second window, and restructuring the semiconductor substrate using the restructured lower third masking layer.
Owner:POLARIS INNOVATIONS LTD

Symmetrical roller type fodder crushing machining device

InactiveCN108325597APrevent solidarity without blankingReduce the phenomenon of slipping and not crushingFeeding-stuffTransportation and packagingDrive shaftEngineering
The invention discloses a symmetrical roller type fodder crushing machining device. The upper portion of a device body is provided with a material bucket, the upper portion of the right side of the device body is provided with a driving motor, and the lower portion of the driving motor is rotationally connected with a driving shaft; the upper portion of the drying shaft is fixedly connected with the first bevel gear; a second bevel gear is fixedly connected with a driven shaft, a driven shaft bearing is rotationally connected with the side wall of the material bucket, and the left end of the driven shaft is fixedly connected with a semi-circular bevel gear; and the left side of the semi-circular bevel gear is provided with two third bevel gears, a toothed part of the semi-circular bevel gear is meshed with the third bevel gears, and the third bevel gears are fixedly connected with a threaded sleeve. According to the symmetrical roller type fodder crushing machining device, the semi-circular bevel gear drives the upper third bevel gear and the lower third bevel gear to rotate forwards and reversely in a reciprocating mode, accordingly, the threaded sleeve is driven to rotate forwards and reversely, the threaded sleeve drives a screw rod and a movable transverse plate to move up and down, partition panels are driven to swing back and forth through connection rods, and accordingly, intermittent discharging is achieved; and a worm drives a worm wheel and a driving roller to rotate for crushing, crushing is more thorough, the transmission torque of the worm and the worm wheel islarge, and the phenomenon that the driving roller slides and cannot crush fodder is avoided.
Owner:赵志坚

Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin

Methods for delivering an effective amount of insulin to the central nervous system to treat Social Communication Disorder while minimizing systemic exposure to the administered insulin. The present invention provides these advantages by administering at least an effective amount of insulin and / or pharmaceutical composition(s) thereof, to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and delivering an effective amount of insulin and / or pharmaceutical compound(s) thereof directly to the CNS. Further methods comprise administering an at least an effective amount of therapeutic agents to the amniotic fluid surrounding a fetus with a treatable neurologic agent or a preventable neurologic condition. For example, administering the at least effective amount of insulin to the amniotic fluid of a fetus with a mother diagnosed with gestational diabetes may prevent the fetus from developing Social Communication Disorder or autism.
Owner:HEALTHPARTNERS RESEACH FOUND

Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin

ActiveUS20150283065A1No to minimal systemic exposureProtect the brainPeptide/protein ingredientsPharmaceutical delivery mechanismNasal cavityWhole body
The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and / or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.
Owner:THE HENRY M JACKSON FOUND FOR THE ADVANCEMENT OF MILITARY MEDICINE INC +1

Golfing putter

InactiveUS20050070372A1Easily struckInformation can be usedGolf clubsEngineeringGolf Ball
This invention relates to a golfing putter and, more particularly, a golfing putter (1) for helping golfers strike a golf ball (17) consistently without inducing backspin on the ball. The golfing putter (1) comprises a head (2) fixed to a shaft (3). The head (2) has a front face (7) for striking the golf ball (17), and an upper face (6) disposed in use towards the golfer. The vertical centre of mass (8) is behind an upper portion of the front face (7) of the head (2). The head (2) has at least in a central portion (35) of the front face (7) an inverted L-shaped cross-section with the top face (6) forming an upper arm (36) of the L-shape and the front face (7) forming the front arm (37) of the L-shape. The front arm (37) is thinner than the top arm (36). The head therefore has a vertical centre of mass (8) behind an upper third of the front face (7) of the head (2) above the impact point with the golf ball (17).
Owner:ROBBINS PHILIP CONWAY +2

Device for evaporating calciferous water by means of electrical heating

Apparatus for evaporating calciferous water by means of electrical heating includes an injection nozzle connected to a spray hose arranged in the upper third of an evaporator immediately above a thermostat that is disposed on the bottom side of the evaporator, the distance between the injection nozzle and the thermostat being less than 15 mm, the steam hose being connected to the evaporator via a steam connector, the steam connector having an inside diameter of at least 5 mm, and the evaporator at an angle of inclination of 5° to 10°.
Owner:BERGHAENEL DIETMAR

Thin film magnetic head having multiple layered films determining track width imbedded in an insulating film and method of manufacturing the same

The present invention is to provide a thin film magnetic head intended to increase precision of and to narrow a width which determines a track width of a write thin film magnetic head and to supply a stably high output substantially free from write blurring on a disk, and a method for manufacturing the same. The thin film magnetic head consisting of a magnetic circuit comprising a read head to read information, a lower magnetic film, a magnetic gap and an upper magnetic film formed with a magnetic gap between it and the lower magnetic film; and of a write head comprising a coil positioned between the upper magnetic film and the lower magnetic film and an insulating film for insulting the coil and the upper magnetic film from each other, wherein the upper magnetic film is configured of an upper first magnetic film, an upper second magnetic film and an upper third magnetic film, and the upper first magnetic film is connected to the upper third magnetic film via the upper second magnetic film.
Owner:HITACHI GLOBAL STORAGE TECH JAPAN LTD

Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system

The present invention is directed to methods for reducing systemic absorption of therapeutic compounds or agents while enhancing efficiency of delivery and targeting of intranasal administration of such compounds or agents to the central nervous system. More specifically, use of ultrasound technology in conjunction with intranasal delivery of a therapeutic compound, or pharmaceutical composition, wherein the intranasal delivery is preferably to the upper one third of a patient's nasal cavity, thereby reducing therapeutic compound or agent absorption into the blood. At the same time, the present invention results in reducing the delivery of therapeutic compounds and / or agents to the peripheral tissues, increases therapeutic delivery of the compounds and / or agents to the central nervous system generally, and increases targeting of the therapeutics and / or agents to specific target regions within the central nervous system.
Owner:HEALTHPARTNERS RESEACH FOUND

Method and apparatus for optimal enrichment of co2 for plant production

The invention provides a method for optimal CO2 enrichment for plant production by suspending CO2 tubing in a secured position between both the plant canopy and lighting system within an indoor garden. The method provides for CO2 tubing to be secured to the lighting system of an indoor garden, thus allowing for the CO2 to be evenly dispersed directly over the optimal upper third portion of the plant canopy. By securing the CO2 tubing in the optimal distribution point, the invention also provides a method for users of the CO2 tank “timed release” system of CO2 enrichment to maximize the amount of CO2 over the upper third portion of the plant canopy during the limited time it is released in the indoor garden during the “lights on” portion of the grow cycle. The invention also provides an apparatus for carrying out the method.
Owner:CURRIER DAVID FREDERICK

Combined cabinet

InactiveCN104172750ASave spaceThe space is enlarged without losing the beautySofasCouchesEngineeringBed boards
The invention provides a combined cabinet, which comprises a cabinet body, wherein the cabinet body is formed by a closet and a bed cabinet; the closet and the bed cabinet respectively have a set of cabinet door; the inner part of the closet is respectively arranged to be an upper cabinet body, a middle cabinet body and a lower cabinet body from top to bottom; the upper cabinet body is connected with the middle cabinet body through a second clapboard; the middle cabinet body is connected with the lower cabinet body through a first clapboard; a horizontal clothes rail is arranged on the lower end of the first clapboard; a control mechanism is arranged at the one third part of the side plate from bottom to top shared by the lower cabinet body and the bed cabinet; a bed body is arranged in the bed cabinet, and is formed by a bed plate, a bed rest, a bed mattress and support bed legs. The combined cabinet has the beneficial effects that the bed cabinet and the closet are effectively combined into a whole, so that not only is the space saved, but also the furniture in the house is ensured to be complete; when being needed, the bed body is put down for use, and when being not needed, the bed body is put into the bed cabinet, so that the space is enlarged without losing attractiveness, and the demand of people is fully met.
Owner:TIANJIN ZHONGBAI HONGLIN TECH

Intranasal delivery of modafinil

Modafinil is selectively delivered to the brain, minimizing delivery to the blood, of a person in need thereof by administering to the person a therapeutically-effective dosage of modafinil, wherein the dosage is less than 1 mg, formulated in a lipid microemulsion (LME) and selectively delivered to the upper third of the nasal cavity. The method may be implemented with an intranasal pharmaceutical delivery device loaded with a modafinil composition and adapted to deliver the dosage to the upper third of the nasal cavity.
Owner:SRI INTERNATIONAL +1

Vehicle seat with lateral support element

The invention relates to a vehicle seat with a seat part and with a seat back part for supporting a driver of the vehicle in the sitting position on the vehicle seat, wherein the vehicle seat is characterized by an additional vehicle driver's torso support device which can be disposed outside the seat part and the seat back part and which can be temporarily disposed at least partially in an otherwise seat-free torso support region at the level of or above the upper third of the seat back part in front of the seat back part and laterally off-center on the seat back part, in order to provide support, laterally off-center of the seat back part, at least at the level of the shoulder or chest region of the driver who is sitting on the vehicle seat when he adopts a seated working posture oriented to the side or backwards, wherein the additional vehicle driver's torso support device is disposed so as to be movable by a moving device from a parked position into an additional torso support position in the otherwise seat-free torso support region.
Owner:GRAMMER AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products